Summary |
The Draft resolution number 1069, 19 January 2021 - previously notified through G/SPS/N/BRA/2000 – which changes MRLs and withdrawal periods and includes multiple cultures for the following substances: A26 - AZOXYSTROBIN, C24 - CARBENDAZIM, C60 - ZETA-CYPERMETHRIN, C61 – BETA-CYFLUTHRIN, D06 - DELTAMETRIN, E26 - SPIROMESIPHENE, F20.1 - ALUMINUM PHOSPHITE, F68 - FLUUXAPYROXADE, F69 - FLUPIRADIFURONE, -05FUR. AMMONIUM SALT, I12 - IMAZAPIR, o I13 - IMIDACLOPRIDE, I27 - INDAZIFLAM, P29.1 - PYRAZOSULFUROM-ETHYLIC, P46 - PYRACLOSTROBIN, P50 - PICOXISTRIBIN, T32 - TEBUCONAZOLE, and T54 - TRIFLOXYSTROBIN, was adopted as Normative Instruction number 141, 29 April 2022.
The final text is available only in Portuguese and can be downloaded at: http://antigo.anvisa.gov.br/documents/10181/6384330/IN_141_2022_.pdf/ec42f6b2-b755-4b38- 8546-9c5ae653d24b
This addendum concern: Notification of adoption, publication or entry into force of regulation
|